Video

Dr. Danila on how he chooses among androgen receptor inhibitors in castration-resistant prostate cancer

Author(s):

Urology Times staff

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Daniel C. Danila, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses choosing among the androgen receptor inhibitors darolutamide (Nubeqa), enzalutamide (Xtandi), and apalutamide (Erleada) when treating patients with castration-resistant prostate cancer.

      Related Videos
      Adam Weiner, MD, on therapeutic decision-making in metastatic prostate cancer
      Adam Weiner, MD, on therapeutic decision-making in metastatic prostate cancer
      Fred Saad, MD, FRCP, reacts to FDA approval of darolutamide in mCSPC
      Fred Saad, MD, FRCP, reacts to FDA approval of darolutamide in mCSPC
      1 expert in this video
      Using Ultrasensitive PSA Assays in Routine Practice
      1 expert in this video
      Ultra-Low PSA Response as a Trial End Point or Clinical Decision Point
      Female doctor typing on her laptop computer in medical office | Image Credit: © Rostislav Sedlacek - stock.adobe.com
      Study findings highlight gender gaps in oncology authorship and citation
      Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
      Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
      Jim Hu, MD, on urinary continence recovery across RARP techniques
      Jim Hu, MD, on urinary continence recovery across RARP techniques
      1 expert in this video
      Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC
      1 expert in this video
      Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice
      Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
      Special Report: Tips for PCPs on evaluating prostate cancer risk
      Related Content
      Amy L. Shaver, PhD, PharmD, MPH
      June 5th 2025

      GLP-1 agonist use is rising in men with prostate cancer

      Benjamin P. Saylor
      In 2015, 1245 patients had prostate cancer and had also initiated a GLP-1 or GIP/GLP-1 receptor agonist compared with 69,808 patients in 2024.
      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
      April 27th 2025

      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

      Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
      Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
      Rana R. McKay, MD, FASCO
      June 4th 2025

      COMRADE: Olaparib plus radium-223 improves rPFS in mCRPC

      Benjamin P. Saylor
      “This was a positive study, resulting in a statistically significant improvement in the primary end point of rPFS in the intent-to-treat population," said Rana R. McKay, MD, FASCO.
      Dr. Murphy on increasing diversity in cancer clinical trials
      February 29th 2024

      Dr. Murphy on increasing diversity in cancer clinical trials

      Urology Times staff
      In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
      Michael Ong, MD
      June 3rd 2025

      Subgroup analysis evaluates darolutamide in previously treated mCRPC

      Benjamin P. Saylor
      Clinical benefit rate was observed 5 (27%) patients in cohort 1, 7 (27%) patients in cohort 2, and 2 (11%) patients in cohort 3.
      Alicia Morgans, MD, MPH
      June 3rd 2025

      Phase 3 ARASTEP study to evaluate PSMA PET-CT–detected BCR in prostate cancer

      Benjamin P. Saylor
      “As of April 2025, 616 patients have been randomized,” said Alicia Morgans, MD, MPH.
      © 2025 MJH Life Sciences

      All rights reserved.